Xencor (NASDAQ:XNCR) had its target price hoisted by Wedbush from $42.00 to $44.00 in a research report released on Friday. They currently have an outperform rating on the biopharmaceutical company’s stock.
Other equities analysts also recently issued research reports about the stock. Cantor Fitzgerald reissued an overweight rating on shares of Xencor in a report on Friday, November 23rd. BidaskClub raised shares of Xencor from a hold rating to a buy rating in a report on Thursday, September 20th. Zacks Investment Research raised shares of Xencor from a hold rating to a buy rating and set a $47.00 price target for the company in a report on Friday, August 10th. Finally, BTIG Research assumed coverage on shares of Xencor in a report on Monday, September 10th. They set a buy rating and a $56.00 price target for the company. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of Buy and an average target price of $41.86.
Xencor stock traded down $0.88 during mid-day trading on Friday, reaching $37.59. The company’s stock had a trading volume of 186,654 shares, compared to its average volume of 150,300. The company has a market cap of $2.16 billion, a PE ratio of -35.80 and a beta of 1.79. Xencor has a twelve month low of $19.89 and a twelve month high of $48.38.
Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Monday, November 5th. The biopharmaceutical company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.57. The business had revenue of $29.04 million during the quarter. On average, research analysts predict that Xencor will post -1.53 EPS for the current year.
In related news, insider Paul A. Foster sold 40,000 shares of the company’s stock in a transaction dated Monday, September 17th. The shares were sold at an average price of $46.03, for a total value of $1,841,200.00. Following the completion of the sale, the insider now owns 44,952 shares of the company’s stock, valued at $2,069,140.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder John S. Stafford III sold 1,000 shares of the company’s stock in a transaction dated Friday, September 14th. The stock was sold at an average price of $48.05, for a total transaction of $48,050.00. The disclosure for this sale can be found here. Insiders own 4.70% of the company’s stock.
A number of hedge funds have recently bought and sold shares of XNCR. Vanguard Group Inc. lifted its holdings in Xencor by 33.0% in the third quarter. Vanguard Group Inc. now owns 4,195,674 shares of the biopharmaceutical company’s stock worth $163,506,000 after purchasing an additional 1,040,578 shares during the period. BlackRock Inc. lifted its holdings in Xencor by 28.5% in the second quarter. BlackRock Inc. now owns 4,011,155 shares of the biopharmaceutical company’s stock worth $148,452,000 after purchasing an additional 889,181 shares during the period. FMR LLC lifted its holdings in Xencor by 2.4% in the second quarter. FMR LLC now owns 8,343,753 shares of the biopharmaceutical company’s stock worth $308,802,000 after purchasing an additional 197,259 shares during the period. Opaleye Management Inc. acquired a new stake in Xencor in the second quarter worth about $6,661,000. Finally, Northern Trust Corp lifted its holdings in Xencor by 22.3% in the second quarter. Northern Trust Corp now owns 588,155 shares of the biopharmaceutical company’s stock worth $21,768,000 after purchasing an additional 107,128 shares during the period. 82.17% of the stock is owned by institutional investors and hedge funds.
Xencor Company Profile
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Recommended Story: Market Capitalization
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.